Found: 10
Select item for more details and to access through your institution.
EPCORITAMAB MONOTHERAPY AND COMBINATIONS IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR RICHTER'S SYNDROME: NEW ESCALATION AND EXPANSION COHORTS IN EPCORE CLL‐1.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 828, doi. 10.1002/hon.3166_OT10
- By:
- Publication type:
- Article
DURABLES RESPONSES WITH ANTI‐CD19 ALLOGENEIC CAR T ALLO‐501/501A IN PHASE 1 TRIALS OF RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA (R/R LBCL).
- Published in:
- Hematological Oncology, 2023, v. 41, p. 85, doi. 10.1002/hon.3163_48
- By:
- Publication type:
- Article
Updated follow‐up of BELLWAVE‐001: an open‐label, single‐arm, phase 1/2 study of the efficacy and safety of nemtabrutinib for the treatment of B‐cell malignancies.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 565, doi. 10.1002/hon.3164_423
- By:
- Publication type:
- Article
A low lymphocyte‐to‐monocyte ratio (LMR) predicts PFS, POD24 and OS in previously untreated, high tumor burden follicular lymphoma (FL): an analysis from the RELEVANCE trial.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 290, doi. 10.1002/hon.3164_200
- By:
- Publication type:
- Article
MOSUNETUZUMAB MONOTHERAPY IN ELDERLY/UNFIT PTS WITH FIRST‐LINE DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): SAFETY AND EFFICACY REMAIN PROMISING WITH DURABLE COMPLETE RESPONSES.
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.152_2880
- By:
- Publication type:
- Article
FINAL DATA FROM THE PHASE 3 ALCANZA STUDY: BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN PATIENTS (PTS) WITH CD30‐POSITIVE (CD30+) CUTANEOUS T‐CELL LYMPHOMA (CTCL).
- Published in:
- Hematological Oncology, 2019, v. 37, p. 286, doi. 10.1002/hon.96_2630
- By:
- Publication type:
- Article
ONGOING PHASE 1B/2 TRIALS OF MOSUNETUZUMAB INVESTIGATING NOVEL TREATMENT REGIMENS FOR PATIENTS WITH B‐CELL NON‐HODGKIN LYMPHOMA (NHL).
- Published in:
- Hematological Oncology, 2019, v. 37, p. 564, doi. 10.1002/hon.12_2632
- By:
- Publication type:
- Article
FINAL DATA FROM THE PHASE 3 ALCANZA STUDY: BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN PATIENTS (PTS) WITH CD30‐POSITIVE (CD30+) CUTANEOUS T‐CELL LYMPHOMA (CTCL).
- Published in:
- Hematological Oncology, 2019, v. 37, p. 286, doi. 10.1002/hon.96_2630
- By:
- Publication type:
- Article
ONGOING PHASE 1B/2 TRIALS OF MOSUNETUZUMAB INVESTIGATING NOVEL TREATMENT REGIMENS FOR PATIENTS WITH B‐CELL NON‐HODGKIN LYMPHOMA (NHL).
- Published in:
- Hematological Oncology, 2019, v. 37, p. 564, doi. 10.1002/hon.12_2632
- By:
- Publication type:
- Article
RESPONSE BY STAGE IN CD30-POSITIVE (CD30+) CUTANEOUS T CELL LYMPHOMA (CTCL) PATIENTS RECEIVING BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN THE PHASE 3 ALCANZA STUDY.
- Published in:
- Hematological Oncology, 2017, v. 35, p. 245, doi. 10.1002/hon.2438_109
- By:
- Publication type:
- Article